Selinexor: Ph Ib/II STOMP data

Data from 22 patients in the subcutaneous Velcade bortezomib arm of the dose-escalation portion of the open-label, international Phase Ib/II STOMP trial showed that once- or twice-weekly selinexor plus Velcade and low-dose

Read the full 328 word article

User Sign In